Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6526 to 6540 of 8932 results

  1. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)

    This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.

    Withdrawn guidance

  2. Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy (TA271)

    This guidance has been updated and replaced by NICE technology appraisal guidance 301.

    Withdrawn guidance

  3. Familial breast cancer (CG14)

    This guidance has been updated and replaced by NICE guideline CG41.

    Withdrawn guideline

  4. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (CG144)

    This guidance has been updated and replaced by NICE guideline NG158.

    Withdrawn guideline

  5. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 23.

    Withdrawn guidance

  6. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 22.

    Withdrawn guidance

  7. Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2)

    This guidance has been updated and replaced by NICE’s highly specialised technologies guidance on elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19).

    Withdrawn guidance

  8. Antimicrobial prescribing: cefiderocol (ES31)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

    Withdrawn advice

  9. Parkinson's disease with motor fluctuations: safinamide (ES6)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  10. Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  11. Clostridium difficile infection: fidaxomicin (ESNM1)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice

  12. Type 2 diabetes: lixisenatide (ESNM10)

    This evidence summary has been updated and replaced by NICE advice ESNM26.

    Withdrawn advice

  13. Acute diarrhoea in adults: racecadotril (ESNM11)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  14. Acute diarrhoea in children: racecadotril as an adjunct to oral rehydration (ESNM12)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  15. Actinic keratosis: ingenol mebutate gel (ESNM14)

    This evidence summary has been withdrawn as the licence of ingenol mebutate gel has been suspended.

    Withdrawn advice